The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2022

Filed:

Sep. 19, 2017
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventor:

Marco Davila, Tampa, FL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 35/17 (2015.01); C07K 16/28 (2006.01); A61K 47/65 (2017.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); A61P 35/02 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); A61K 47/65 (2017.08); A61P 35/02 (2018.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C12N 5/0075 (2013.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01);
Abstract

Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.


Find Patent Forward Citations

Loading…